Sterling Winthrop
Executive Summary
Receives Sept. 12 FDA warning letter concerning an Aug. 7 inspection of Sterling's Barceloneta, Puerto Rico facility. Among other charges, the letter states that Sterling has "failed to thoroughly investigate the presence of metal particles" in a lot of Neo Synephrine and "the potential presence of such particles in other lots." The company claims that it responded to the FD-483 issued after the inspection within the deadline and that the response and the warning letter crossed in the mail. Sterling says the Neo Synephrine discoloration, which prompted a May 17 recall of lot B325fl ("The Pink Sheet" July 24, T&G-15), was an isolated incident and that the company has resolved all of the problems cited by FDA. . . .
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth